GlassScriptPhysician profile
Robert G Reuther
NPI 1093738718
$1,400.71
in general payments reported to CMS, 2019-2025
11 companies · $637 in 2025
The $637 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $31.97 · 2021: $98.37 · 2022: $176 · 2023: $155 · 2024: $162 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $954.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $786.72 | 2019-2025 | Clearpath, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Alcon Vision LLC | $337.26 | 2019-2024 | Eysuvis, Clareon |
| Abbvie INC. | $74.61 | 2022-2023 | |
| Oyster Point Pharma, INC. | $41.91 | 2023 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $41.66 | 2022 | |
| Shire North American Group INC | $24.01 | 2019 | |
| Bausch & Lomb Americas INC. | $22.07 | 2023 | Vyzulta, Miebo |
| Sun Pharmaceutical Industries INC. | $21.56 | 2022 | |
| Glaukos Corporation | $19.53 | 2025 | Idosetr |
| Rayner Intraocular Lenses Limited | $18.30 | 2022 | |
| Allergan, INC. | $13.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Reuther listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.